NGM Biopharmaceuticals: Eye Disorder Data Due 2nd Half Of 2022 (NASDAQ:NGM)
Seeking Alpha· 6 days agoThis will be the release of results from the phase 2 CATALINA study using NGM621 for the treatment...
LumiThera Presents US LIGHTSITE III Trial Data Showing Improvement in Vision in Intermediate Dry...
WFMZ Eastern Pennsylvania and Western New Jersey· 5 days agoSEATTLE, June 22, 2022 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company...
Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related ...
Morningstar· 3 days agoKinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001 ...
Morphology of en face Haller vessel and macular neovascularization at baseline and 3 months as...
Nature· 2 days agoThe inclusion criteria were age 50 years or older, treatment-naïve nAMD confirmed by multimodal retinal imaging (fluorescein angiography, indocyanine green angiography, and ...
Supplements warning: The vitamin linked to a ‘rapid' reduction in vision ‘over minutes'
MSN News· 2 days agoUNLIKE drugs, supplements are not intended to treat, prevent or cure diseases, but instead are...
Apellis (APLS) Expands Deal for Targeted Complement Therapies
Zacks via Yahoo Finance· 4 days agoApellis (APLS) expands its current research and development deal with privately held company,...
Cost of ranibizumab port delivery system for treating nAMD examined
Medical Xpress· 4 days agoFor patients with neovascular age-related macular degeneration (nAMD), ranibizumab with a port...
EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors
Morningstar· 4 days agoDr. Adamis is a highly accomplished ophthalmology executive with more than 30 years of research and development experience in the biopharmaceutical industry. “Dr. Adamis is a pioneer in the ...
Adverum Biotechnologies Obtains EMA’s Priority Medicines Status For Chronic Eye Disorder Candidate -...
Benzinga· 3 days agoThe European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ ADVM lead drug ADVM-022 for the treatment of wet age-related ...
Foundation Fighting Blindness Announces Leadership Changes
WBAY Green Bay· 6 days agoThe Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, announced today the promotions ...
Yahoo Web Search
Trending Now
